Cite
HARVARD Citation
Smolen, J. et al. (2015). Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the rheumatic diseases. 74 (5), pp. 843-850. [Online].